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Abstract: There are more than 100 recognized disorders of the eye. This makes the development
of advanced ocular formulations an important topic in pharmaceutical science. One of the ways
to improve drug delivery to the eye is the use of penetration enhancers. These are defined as
compounds capable of enhancing drug permeability across ocular membranes. This review paper
provides an overview of anatomical and physiological features of the eye and discusses some common
ophthalmological conditions and permeability of ocular membranes. The review also presents the
analysis of literature on the use of penetration-enhancing compounds (cyclodextrins, chelating agents,
crown ethers, bile acids and bile salts, cell-penetrating peptides, and other amphiphilic compounds)
in ocular drug delivery, describing their properties and modes of action.
Keywords: ocular drug delivery; cornea; penetration enhancers; ocular conditions; ophthalmology
1. Introduction
According to the World Health Organization, the number of people who live with some form of
distance or near vision impairment is about 1.3 billion worldwide [1]. This problem is very important
because approximately 80% of external input of information delivered to the brain is processed by the
visual pathway [2]. There were many methods and improvements of ocular drug delivery developed
over the last decades exploring more effective treatments for different ocular diseases. Nevertheless,
this field of medicine remains one of the most challenging.
The preferred method of ocular drug delivery is via topical application due to ease of access to
the eye and the non-invasive nature of this administration route [3]. Self-medication by this means is
achievable by most people that are not limited by dexterity issues or conditions affecting mental ability.
Administration by a helper eliminates these potential difficulties. Ocular drug penetration is possible
via the transcellular pathway, i.e., into and through cells, or the paracellular route, i.e., between cells,
or a combination of both pathways [4].
Drug penetration enhancement can be achieved by inclusion of agents capable of modifying
the tear film, mucous layer, and ocular membranes in a drug formulation [5]. A further strategy for
enhancing drug penetration into the eye can be achieved by energy-driven means, where a small
electrical current is used (iontophoresis) [6] or ultrasound is employed to drive the drug to enter the
ocular tissues [7–9]. The use of microneedles for enhanced ocular drug delivery is another emerging
area of research; however, this could be considered somewhat invasive and inconvenient [10–12].
Penetration enhancers are compounds that are able to enhance drug delivery across otherwise
impermeable or limited permeability membranes such as the cornea, acting predominantly on the
epithelia [5]. The use of penetration enhancers in transdermal applications is a well-established
approach to facilitate drug delivery across the skin and this topic was covered in a number of excellent
reviews [13,14]. Ocular drug delivery is still lacking good understanding and analysis of the effects of
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various penetration enhancers. It is, however, already established that penetration enhancers in ocular
drug delivery facilitate delivery of active pharmaceutical ingredients through three main mechanisms
or their combination [15,16]:
1. Altering tear film stability and the mucous layer at the ocular surface [17,18];
2. Modifying membrane components such as lipid bilayers of associated epithelial cells [19];
3. Loosening epithelial tight junctions [4,17].
Penetration-enhancing excipients for use in ocular formulations should ideally have the following
characteristics: they should be non-toxic and non-irritating, efficacious at low concentrations, fast-acting,
and their effect should be reversible [20,21].
This paper provides an overview of anatomy and physiology of the eye, discusses some common
ophthalmological conditions, and presents an analysis of literature on the use of penetration enhancers
in ocular drug delivery.
2. Ocular Anatomy and Physiology
The visual system is a sensory unit helping us to understand our environment, comprising a
receptor (retina), sensory pathway (optic tract), and brain center (primary visual cortex). Each eyeball is
embedded within the orbit, which is a pear-shaped cavity physically protecting the eye [1,22]. Adipose
tissue surrounds the eye within the orbital cavity and helps to cushion the eye. Other accessory organs
include lacrimal glands, eyebrows, eyelids, eyelashes, and muscles of the eye. The human eye is a
complex organ comprising three different coats or layers, enclosing various anatomical structures as
shown in Figure 1. Below, we briefly consider some specific tissues in the eye.
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Figure 1. Anatomy of the human eye: 1—cornea; 2—meibomian glands; 3—palpebral conjunctiva; 
4—bulbar conjunctiva; 5—conjunctival fornix; 6—sclera; 7—iris; 8—anterior chamber; 9—
iridocorneal angle; 10—ciliary body; 11—lens; 12—posterior chamber; 13—suspensory ligament; 14—
choroid; 15—retinal pigmented epithelium; 16—retina; 17—vitreous body; 18—optic disc; 19—optic 
nerve; 20—central artery and vein of the retina; 21—fovea. 
2.1. The Outermost Layer (Tunica Fibrosa Oculi) 
The fibrous tunic helps maintain the spherical shape of the eyeball and consists of the cornea and 
sclera. It is well known that less than 5% of the topically applied drug penetrates through the cornea 
[23]. However, the most accessible regions for drug application are the conjunctiva, sclera, and cornea. 
The cornea is an avascular, transparent, highly innervated structure, whose average diameter is ∼11.5 
mm vertically and ∼12 mm horizontally. The average thickness of this structure is ∼540 μm in the central 
part, and it is thicker toward the periphery [22]. The refractive power of this structure in the eye is 
roughly 42 diopters. The cornea is covered with the tear fluid, forming a film that protects its surface 
from dust and other particles. This film consists of three layers as shown in Figure 2: the outer lipid 
layer (delivered to the lid margins from the meibomian glands located within the tarsal plate) [24], 
middle aqueous layer (produced by the lacrimal gland, containing free lipid and soluble mucin), and 
mucous layer (which is mainly secreted by the goblet cells located within the conjunctiva as single cells 
with the highest density of those in the conjunctiva of the inferior eyelid) [25].  
i re 1. at f t e a e e: 1 c r ea; 2 ei ia la s; 3 al e ral c j cti a;
4 l ar conjunctiva; 5—conju ctival fornix; 6—sclera; 7—iris; 8 anterior chamber; 9—iridocorneal
angle; 10—ciliary body; 11—lens; 12—posterior chamber; 13—suspensory ligament; 14—choroid;
15—retinal pigmented epith lium; 16—retina; 17—vitreous body; 18—optic disc; 19—optic nerve;
20—central artery nd vein of the retina; 21—fovea.
2.1. The Outermost Layer (Tunica Fibrosa Oculi)
The fibrous tunic helps maintain the spherical shape of the eyeball and consists of the cornea
and sclera. It is well known that less than 5% of the topically applied drug penetrates through the
cornea [23]. However, the most accessible regions for drug application are the conjunctiva, sclera, and
cornea. The cornea is an avascular, transparent, highly innervated structure, whose average diameter
is ~11.5 mm vertically and ~12 mm horizontally. The average thickness of this structure is ~540 µm in
the central part, and it is thicker toward the periphery [22]. The refractive power of this structure in
the eye is roughly 42 diopters. The cornea is covered with the tear fluid, forming a film that protects
its surface from dust and other particles. This film consists of three layers as shown in Figure 2: the
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outer lipid layer (delivered to the lid margins from the meibomian glands located within the tarsal
plate) [24], middle aqueous layer (produced by the lacrimal gland, containing free lipid and soluble
mucin), and mucous layer (which is mainly secreted by the goblet cells located within the conjunctiva
as single cells with the highest density of those in the conjunctiva of the inferior eyelid) [25].Pharmaceutics 2019, 11, x FOR PEER REVIEW 3 of 32 
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epithelium. The high lipophilicity of the epithelium allows permeability to up to 90% of lipophilic 
small drug molecules and only about 10% of hydrophilic molecules. The cells of this layer have Ca2+-
dependent membrane adherent regions; tight junctions are formed between the zonula occludens, 
zonula adherens, and desmosomes [5]. The epithelium protects the eye against ultraviolet radiation 
(UVR) by means of a high concentration of tryptophan residues and ascorbate that absorb UVR [26]. 
The next layer that is placed right underneath the epithelium is the Bowman’s membrane that is also 
called the anterior limiting membrane. Bowman’s layer is acellular and composed primarily of 
collagen. The anterior limiting membrane reaches from 8 μm to 14 μm in thickness. The middle 
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The next layer that is placed right underneath the epithelium is the Bowman’s membrane that is
also called the anterior limiting membrane. Bowman’s layer is acellular and composed primarily
of collagen. The anterior limiting membrane reaches from 8 µm to 14 µm in thickness. The middle
corneal layer is the stroma, also known as substantia propria due to the fact that it makes up to 90%
of the total thickness of the cornea. It is composed of about 80% of water and collagen, proteins,
mucopolysaccharides, and proteoglycans [5]. In 2013, Dua et al. reported a discovery of an additional
corneal layer that was not detected previously [27]. According to Dua et al., this layer is about 15 µm in
thickness and is located between the corneal stroma and the fifth corneal layer, Descemet’s membrane.
This is also the posterior limiting membrane of the cornea. This membrane is a ~6-µm-thick basement
of the endothelium cells. The innermost layer of the cornea is known as the endothelium and plays the
role of a pump, providing the cornea with the correct hydration to ensure transparency of this tissue.
The clarity of the cornea depends on an ordered lamellar collagen structure and relative dehydration
which requires endothelial cell density of at least 1000 cells/mm2. According to the literature, there is
a loss of the human cornea mean endothelial cell density in normal eye by approximately 0.6% per
year [28]. The endothelium is ~5 µm in thickness and consists of a monolayer of squamous or low
cuboidal cells [5].
Another layer providing the eyeball with protection is called the conjunctiva, of which all three
portions are shown in Figure 4. The palpebral conjunctiva has blood vessels and covers the posterior
surface of the upper and lower lids. The conjunctiva comprises two or more layers of isoprismatic to
highly prismatic epithelial cells. The bulbar conjunctiva is an avascular slightly mobile layer that starts
from the upper and lower fornices and lies over the sclera up to the cornea region. This anatomical coat
consists of stratified non-keratinized epithelial cells [29]. The superior and inferior fornices form the
conjunctival sac, which can act as a reservoir for instilled medicine or the placement of a drug-loaded
ocular insert [30,31]. According to the literature, the estimated total area of the human conjunctival sac
is approximately 16 cm2 [24]. Figure 4 clearly demonstrates all three portions of the conjunctiva.
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The tough outer layer of the eye globe is called the sclera. This is covered by the episcleral, a 
loose connective tissue layer. In the anterior part of the eye, the sclera lies up to the corneal limbus, 
and posteriorly to the optic nerve. This layer comprises collagen, proteoglycans, elastin, and 
glycoproteins. These collagen bundles are not uniformly oriented, which results in the opaque but 
mechanically strong nature of the sclera. The sclera itself is pierced by a number of blood vessels, 
while being effectively avascular itself [32]. 
2.2. Eye Chambers, Iris, Ciliary Body, and Lens 
One of the first intraocular structures that can be partially seen, due to the corneal transparency, 
is the anterior chamber of the eye. This is a space between the cornea’s endothelium and anterior 
surface of the iris that is filled with aqueous humor. The latter is an optically clear fluid resembling 
blood plasma. The aqueous humor helps maintain appropriate intraocular pressure (IOP), and 
provides the cornea, trabecular meshwork, and lens with nutrition and oxygen, while removing 
metabolic wastes, as well as delivering molecules of neurotransmitters [33].  
This fluid is formed and delivered to the posterior chamber by nonpigmented cells of the 
epithelia via ciliary processes [34]. Then, it flows through the pupil into the anterior chamber where 
two ways of outflow are found (Figure 5): (1) the conventional route is the primary outflow, where 
the aqueous humor is drained through the trabecular meshwork located at the anterior chamber 
angle (iridocorneal angle) to the Schlemm’s canal (circular tube located in the limbus, 1-mm-wide 
region of merging epithelium of cornea and sclera), which delivers it directly into aqueous veins [35]; 
(2) uveoscleral outflow is provided by means of the iris root and the ciliary body face, where the 
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The tough outer layer of the eye globe is called the sclera. This is covered by the episcleral, a loose
connective tissue layer. In the anterior part of the eye, the sclera lies up to the corneal limbus, and
posteriorly to the optic nerve. This layer comprises collagen, proteoglycans, elastin, and glycoproteins.
These collagen bundles are not uniformly oriented, which results in the opaque but mechanically
strong nature of the sclera. The sclera itself is pierced by a number of blood vessels, while being
effectively avascular itself [32].
2.2. Eye Chambers, Iris, Ciliary Body, and Lens
One of the first intraocular structures that can be partially seen, due to the corneal transparency, is
the anterior chamber of the eye. This is a space between the cornea’s endothelium and anterior surface
of the iris that is filled with aqueous humor. The latter is an optically clear fluid resembling blood
plasma. The aqueous humor helps maintain appropriate intraocular pressure (IOP), and provides the
Pharmaceutics 2019, 11, 321 5 of 33
cornea, trabecular meshwork, and lens with nutrition and oxygen, while removing metabolic wastes,
as well as delivering molecules of neurotransmitters [33].
This fluid is formed and delivered to the posterior chamber by nonpigmented cells of the epithelia
via ciliary processes [34]. Then, it flows through the pupil into the anterior chamber where two ways
of outflow are found (Figure 5): (1) the conventional route is the primary outflow, where the aqueous
humor is drained through the trabecular meshwork located at the anterior chamber angle (iridocorneal
angle) to the Schlemm’s canal (circular tube located in the limbus, 1-mm-wide region of merging
epithelium of cornea and sclera), which delivers it directly into aqueous veins [35]; (2) uveoscleral
outflow is provided by means of the iris root and the ciliary body face, where the aqueous humor
crosses between fibers of the muscle into the supraciliary and suprachoroidal spaces and is collected
by the choroidal blood circulation. The proportion of aqueous outflow via each route could be
different according to the age and disease [36]. The aqueous humor consists of inorganic and organic
ions, carbohydrates, glutathione, urea, amino acids, proteins, oxygen, carbon dioxide, and water.
According to the literature, the concentration of Na+ in the aqueous humor is almost the same as in the
blood plasma, while the concentration of proteins is 200 times lower compared to plasma levels, and
ascorbate’s concentration is 20 to 50 times higher [33].
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Pathways of aqueous humor outflow are indicated with arrows. 1—cornea; 2—sclera;
3—anterior chamber; 4— upil; 5—iris; 6—ciliary body; 7—lens; 8—suspensory liga e t;
The anterior chamber houses the iris, which separates anterior and posterior segments. Being
attached to the anterior part of the ciliary body fro the periphery, this anato ical structure has an
aperture in its center that is called the pupil, the diameter of which can be regulated by the sphincter and
dilator muscles located within the iris stroma (vascular connective tissue) to control the amount of light
transmitting into the eye. At the posterior part of the iris, there are two epithelial layers—the anterior
layer is slightly pigmented, while the posterior one has a high density of pigmentation and faces the
posterior chamber. Just behind the iris lies another part of the uveal tract called the ciliary body. As
already mentioned, production of the aqueous humor and uveoscleral outflow are among its functions.
Additionally, the ciliary body is responsible for hyaluronate production and its release into the vitreous
body, as well as for being a part of the accommodation mechanism due to the circular muscle fibers
within the ciliary body. Also, this structure of the eye plays an important role in maintaining the
blood–aqueous barrier [37].
The capsular bag is situated between the iris and the vitreous body and encapsulates the crystalline
lens, hich is a transparent biconvex avascular structure enclosed in the elastic capsule co posed of
collagen and that is attached to the ciliary body ith the help of zonular fibers (the zonule of Zinn).
Interestingly, the thickness of the anterior part of the capsular bag gro s fro 12–15 µ to 21 µ
throughout life. Conversely, the thickness of the posterior part re ains at about 2 µ . It is ell kno n
that the lens is the second most powerful refractive structure of the eye (after the cornea). It helps
refract incoming light and focuses it onto the retina. When light is focused at a short focal distance, the
suspensory liga ents are not under tension due to contraction of the ciliary uscle; thus, the lens
thickens and results in higher refractive po er. At the sa e ti e, distance vision requires the ciliary
uscle to relax and, hence, to tense the lens-supportive apparatus hich flattens the lens. Regarding
the icroscopic structure of the lens, it is co posed of t o types of cells. The cuboidal lens epithelial
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cells form a single layer that lines the anterior hemisphere, enlarging in the equator region and forming
the lens “bow”. The cells in this region function as stem cells for the lens. The bulk of the lens consists
of lens fibers that differentiate to the point where no lens nucleus remains. These fiber cells extend in
concentric layers from the anterior lens pole to the posterior one, where junctions at the terminus of
the cells form the lens sutures [38]. The transparency and refractive properties of the lens are due to
the uniform concentration gradient of the crystallins (α-, β-, γ-crystallins) that represent about 90% of
the water-soluble proteins [39].
The third chamber of the eye is called the vitreous body, which is positioned at the back of the
eyeball between the lens and the retina. It is a clear, gel-like substance occupying the main volume
of the eye and is composed of long fine collagen fibers, proteins (over 80% of those are albumin and
immunoglobulins), fibrillins, fibulins, agrin, opticin, pigment epithelium-derived factor, leucine-rich
alpha-2 glycoprotein, thrombospondins, hyaluronic acid, polysaccharides, ascorbic acid, and water
(about 98% of the whole volume). The vitreous body has no circulatory flow; hence, molecular
movements are driven mostly by diffusion. Although the vitreous body is a remarkably stable structure,
there is a gradual tendency for the gel to collapse in the course of a lifetime. This is commonly believed
to be a result of degradation or alteration of the collagen fiber network. Moreover, the volume of the
vitreous gel is about 4 mL at the age of 20 years, starting to gradually decrease after 40 years to less
than 2.5 mL at 80 years [40–42].
2.3. Choroidea and Retina
The choroid is a vascular layer located between the sclera and Bruch’s membrane (BM) extending
from the ora serrata (region of the anterior edge of the retina) to the optic nerve. The choroid coat
includes five distinct regions: (1) BM—thin, acellular extracellular matrix positioned right under the
retina which acts like a filter to the retina; (2) the choriocapillaris (provides the outer retina with oxygen
and nutrients); (3) layer with small and medium-sized vessels; (4) layer with large vessels; and (5) the
suprachoroid. Apart from BM and the layer with choriocapillaris, the remainder of the choroidea, the
stroma, is populated with melanocytes, connective tissue elements (including fibroblasts, mastocytes,
elastic, and collagen fibrils), blood vessels, macrophages, dendritic cells, lymphocytes, nonvascular
smooth muscle cells, intrinsic neurons, and nerve fibers associated with vessels [43–45].
The retina is a complex transparent tissue of ~0.55 mm at the edges of the fovea and of ~0.13 mm
at the center (umbo). This innermost layer of the eye includes a nonsensory part and an optic part that
are divided by the ora serrata. The anterior part does not provide any sensory function and covers the
ciliary body and iris with bilaminar epithelium. The posterior portion of the retina lies from the ora
serrata to the optic disc being attached only at these two locations. Interestingly, there is an area on
the optic retina, roughly 5.5 mm in diameter, which is centered about 4 mm temporal to and 0.8 mm
inferior to the center of the optic disc that is called macula (macula lutea or central retina) and which
has xanthophyll and two or more layers of ganglion cells. Moreover, few regions can be distinguished
within this part of the retina: (1) the fovea (fovea centralis) is a depression in the center of the macular
area (~1.5 mm in diameter); (2) the foveola is a central floor of the fovea, which is approximately
0.35 mm in diameter; and (3) the umbo (central depression of the foveola). The optic part of the retina is
composed of the retinal pigmented epithelium (RPE; the outer layer) and the cerebral layer (inner). RPE
supplies the neurosensory layer with nutrition, as well as removes metabolic products. Additionally,
it plays a key role in maintaining the blood–retina barrier (BRB) separating the neurosensory retina
from the circulating blood. The inner retina comprises photoreceptors (approximately 120 million
rods and 6–7 million cones that constitute the first neuron), bipolar cells (the second neuron), and
multipolar ganglion cells (the third neuron), along with horizontal and amacrine cells. Interestingly,
rod cells are responsible for peripheral vision acting at low light levels using the photosensitive
molecule (rhodopsin) in visual phototransduction. In contrast, three types of cone cells (according
to the color perception: red, blue, and green) are located only within the fovea area and are 30- to
100-fold less sensitive compared to rod cells, requiring the simultaneous activation of tens to hundreds
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of visual pigment molecules (that are homologous or even identical to those found in rods) to generate
a detectable response resulting in their activity at relatively high light levels, thereby providing central
vision and the ability to distinguish colors. Therefore, the retina is the site of transformation of light
energy into a neural signal that is transmitted via the optic nerve to the visual cortex to be analyzed by
the brain helping to “see” the environment [29,46,47].
3. Ocular Conditions
There are more than 100 recognized disorders of the eye [22]. Therefore, only some of the most
common disorders or the conditions that could potentially benefit from the development of advanced
topical formulations with enhanced drug permeability are briefly discussed here. Most frequent
diseases of the cornea include keratitis, keratoconus, and dry eye syndrome.
Keratitis is a condition when the patient’s cornea becomes inflamed. A wide range of
germs could lead to this inflammatory condition, but the most common are Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa, Neisseria gonorrhoeae,
Haemophilus, herpes simplex and varicella zoster viruses, Fusarium, Aspergillus, Candida, and
acanthamoeba. Patients typically complain of pain, foreign body sensation, photophobia, redness of
the eye, tearing, discharge (sometimes purulent), and decreased visual acuity. Although this condition
is mostly quite painful for the patient and requires urgent treatment, sometimes it can be almost
asymptomatic (for instance, if caused by acanthamoeba).
Antibacterial drops combined with subconjunctival injections in severe cases are the choices of
therapy in patients with keratitis. According to the most recent clinical recommendations [48], two main
schemes are used to treat bacterial keratitis depending on the pathogen and the response to its therapy.
The monotherapy includes the use of antibacterial eye drops consisting of fluoroquinolones (levofloxacin,
moxifloxacin, gatifloxacin, besifloxacin, ofloxacin, or ciprofloxacin) that cover both Gram-positive
(Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae) and Gram-negative
(Pseudomonas aeruginosa, Neisseria gonorrhoeae, Haemophilus) bacteria. However, these medications
should be used with caution due to the possible resistance of some organisms, which can be noticed
by controlling the clinical response. Therefore, there is a second treatment scheme, which combines
fluoroquinolone eye drops and solutions for a topical or subconjunctival route that comprise other
groups of antibiotics including cephalosporin (cefazolin, ceftazidime), aminoglycosides (gentamicin
or tobramycin), penicillins (penicillin G, methicillin, or piperacillin), and glycopeptide antibiotics
(vancomycin). For instance, cefazolin is commonly used for Pseudomonas aeruginosa infection. On the
other hand, ceftazidime is effective against resistant forms of Pseudomonas aeruginosa. Vancomycin
has efficacy against methicillin-resistant staphylococci, as well as against other Gram-positives.
Additionally, corticosteroids (dexamethasone, prednisolone) can be used topically in terms of
reducing pain and inflammation in bacterial keratitis but with caution, keeping in mind they inhibit
re-epithelialization of the cornea [49,50]. Treatment with steroids should be avoided, when keratitis is
induced by fungi or acanthamoeba, as well as in cases of any doubts regarding the effectiveness of the
antimicrobial regimen.
Nonsteroidal anti-inflammatory drugs (NSAIDs) also may be recommended for reducing
symptoms of inflammation only in the case of efficient antimicrobial therapy. In addition,
preservative-free lubricants may be used for promoting healing and cycloplegic agents (cyclopentolate)
to reduce discomfort associated with spasm of the ciliary body, as well as for decreasing formation of
synechiae [48].
Topical usage of antiviral eye drops (acyclovir) is the core of treatment in cases of herpes simplex
keratitis. Eye drops with trifluorothymidine or ganciclovir can be prescribed instead of acyclovir in
cases of resistance to therapy. Also, prednisolone acetate- or dexamethasone-including eye drops
are used to reduce the inflammation, albeit with the caveat regarding epithelial damage discussed
above. In terms of preventing virus reactivation, the administration of oral antiviral agents is preferred.
Conversely, in patients with keratitis induced by varicella zoster virus (herpes zoster ophthalmicus),
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Dworkin et al. [51] reported that topical antiviral therapy is ineffective. Hence, systemic usage of
antiviral drugs is the choice of treatment. Additionally, cycloplegic eye drops (cyclopentolate) are
used for preventing ciliary spasm that can be associated with this pathological condition. Topical
preservative-free lubricants such as hydroxypropyl methylcellulose (and others) can also be added to
the treatment [48].
Fungal keratitis should be generally treated with topical antifungal formulations that can be
divided into a few groups depending on their mode of action: polyenes (amphotericin B, natamycin),
imidazoles (clotrimazole, miconazole, econazole, ketoconazole), triazoles (itraconazole, fluconazole,
voriconazole), pyrimidines (flucytosine), and echinocandins (micafungin, caspofungin) [49]. Systemic
antifungal drugs can be recommended in severe cases involving deep stromal layers with a high risk of
perforation of the cornea. Additionally, topical cycloplegic drugs can be used. The keratitis caused by
acanthamoeba should be treated with topical anti-amoebic formulations [48]. Of note, the aim of this
treatment is to eradicate amoebic cysts from the cornea. The first-line therapy includes biguanide agents
(polyhexamethylene biguanide (PHMB), chlorhexidine) that are cystidical (active against cysts). The
aromatic diamidines (propamidine, hexamidine) belong to the second-line medications providing more
variable activity, along with being cystidical. In contrast, aminoglycosides (neomycin, paromomycin)
or azole agents (clotrimazole, fluconazole, ketoconazole, miconazole) are almost not cystidical, being
active against trophozoites [49]. However, they can be used in addition to first- or second-line therapy.
According to the literature, adenylate cyclase can be administered topically to promote the conversion
of cysts into a protozoal state [48].
Keratoconus is defined by Kanski and Bowling as a progressive disorder in which thinning of the
central or paracentral stroma of the cornea occurs, accompanied by apical protrusion and irregular
astigmatism [22]. It affects 0.05–5% of the population [48]. Patient complaints include blurred vision,
mild photophobia, and increased vision impairment due to progressive myopia and astigmatism. The
cause of this condition is still unknown, but some authors refer to such factors as combination of
repeated trauma and existing abnormalities of the stroma. Additionally, in some cases, keratoconus
presents in patients with other ocular and systemic conditions including, for example, disorders of
the connective tissue. One widely used method for treatment of this condition is a corneal collagen
cross-linking, which leads to stabilization of ectasia by using riboflavin eye drops and subsequent
exposure to ultraviolet-A light. Also, implantation of the ring segment within the cornea can be used
as an addition to the cross-linking procedure. In severe cases, keratoplasty (corneal transplantation) is
a choice of treatment [22].
Dry eye disease (keratoconjunctivitis sicca) occurs in cases of inadequate tear volume or function,
which results in an unstable tear film with disease of the surface of the eye. The prevalence of dry eye
syndrome in American and Australian population is estimated to be around 5–16%, while in Asia it is
higher and could reach up to 27–33% [49]. Severity of the symptoms may highly vary from patient
to patient, but they mostly include a feeling of burning and blurred vision. Pathologies affecting
the lacrimal gland and dysfunction of the Meibomian glands, as well as neurological diseases, can
lead to the keratoconjunctivitis sicca [22,32]. The aim of therapy is to restore the normal surface of
the eye by using tear supplementation along with inhibiting the aberrant inflammation observed
in patients with chronic dry eye syndrome. Treatment of this condition is complex, but only the
most common topical ocular formulations are discussed in this paper. The following groups of
medicines are recommended: lubricants (carboxymethylcellulose, hydroxypropyl methylcellulose, and
carbomer gels), hydroxypropyl guar/sodium hyaluronate or combinations (carboxymethylcellulose,
polysaccharides or disaccharide), xanthan gum, phospholipids and soybean), artificial tears (with
various electrolyte compositions, viscosity, and presence of preservatives), and eye drops with
cyclosporine A (increasing tear production by reducing the inflammation of the lacrimal gland).
However, lifitegrast is a topical anti-inflammatory medicine which is, at the moment, the only drug
approved by the Food and Drug Administration for treating both symptoms and signs in patients with
dry eye disease [48,49].
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Cataract is a condition in which opacification of the crystalline lens occurs principally as a result
of protein aggregation. According to some studies, the number of people in the world who become
blind due to cataract is estimated as 20 million [52]. The Vision Loss Expert Group funded by the Bill
and Melinda Gates Foundation, Fight for Sight, and others calculated that cataracts led to blindness
in 10.6 million people and moderate to severe visual impairment in 34.4 million people [49]. A few
classifications are used (depending on morphology, etiology, and maturity) but, in general, all cataracts
can be divided into two groups: congenital and acquired. Among the latter group, one of the common
types is the age-related cataract induced by metabolic processes of aging (including oxidative stress)
of the human lens. Clinicians can hear from patients such symptoms as decreased visual acuity,
changing of the contrast sensitivity, color perception, glare, monocular diplopia, and ghosting [48].
Surgical removal of the natural lens and its replacement with an intraocular lens (IOL) is currently
the only solution for patients with this condition. However, scientists are actively searching for a
potential topical treatment. Thus, it was found that pyruvate eye drops can effectively penetrate ocular
membranes and potentially provide protection against oxidative stress [53], while Zhao et al. reported
that using lanosterol-loaded nanoparticles can reverse protein aggregation in the lens [54].
Glaucoma is a progressive optic neuropathy that is accompanied by the excavation of the optic
nerve head and a loss of visual sensitivity in the sequence beginning in the mid-peripheral visual field.
Types of glaucoma are classified as open-angle, angle-closure, glaucoma due to another disease, and
childhood onset glaucoma [55,56]. It is worth noting that the leading cause of irreversible blindness
worldwide is glaucoma. The following indicators are considered as risk factors for developing glaucoma:
increasing age (mostly after 40 years), race, family history, and using steroids. One of the major risks
for the development and progression of glaucoma is intraocular pressure (IOP). The prevalence of this
condition is 3.54% for people aged 40–80 years worldwide [56]. Even in normal-tension glaucoma
with IOP not exceeding 21 mmHg, IOP remains a risk factor for progressive damage of the optic
nerve [49]. One of the reasons why patients may not ask for medical help until developed stages
of the disease occur is that it is usually asymptomatic. In some cases, patients may complain of
halos, pain in the eye, headache, precipitants, and subjective loss of vision field [32]. Pharmacological
treatment of glaucoma includes five main groups of topical formulations (prostaglandin analogues,
beta-blockers, sympathomimetics (alpha-2-agonists), carbonic anhydrase inhibitors, and miotics). Eye
drops with prostaglandin analogues (latanoprost, travoprost, bimatoprost, tafluprost) are considered
to be a first-line therapy in open-angle glaucoma patients to reduce the IOP primarily by increasing
uveoscleral outflow. A number of side effects (conjunctival hyperemia, irreversible hyperpigmentation
of iris, reversible increasing pigmentation of the lid skin, lengthening along with thickening of eyelashes,
and orbital fat loss), as well as limitations of using these therapies in inflamed eyes and in patients with
herpetic keratitis in their anamnesis, may lead to replacing prostaglandin derivatives with beta-blockers.
The latter IOP-lowering class of drugs reduces aqueous production and can be divided into two kinds
of beta-blockers depending on the involved receptors: non-selective (timolol, carteolol, levobunolol)
and β1-selective (betaxolol). However, the use of beta-blockers is relatively restricted in patients
with asthma and cardiovascular diseases due to the potential bronchospasm, hypotension, heart
block, and bradycardia. The carbonic anhydrase inhibitors (brinzolamide, dorzolamide) represent
another type of topical formulations, which also lower levels of aqueous humor production, being
contraindicated in patients with an allergy to sulfonamide antibiotics and patients with renal or
liver failure. The mode of action of sympathomimetics (brimonidine and apraclonidine) is based
on the stimulation of alpha-2-receptors, resulting in both the decrease of the aqueous secretion
and enhancement of the uveoscleral outflow. On the other hand, bradycardia and heart block are
among the contraindications for the use of these sympathomimetics. Alpha-2 agonists are mostly
prescribed for short-term use (for instance, after laser iridotomy). The treatment of angle-closure
glaucoma includes the use of miotics (pilocarpine and carbachol) that increase the outflow through the
trabecular meshwork. Currently, numerous combined preparations are commercially available on the
market (timolol and dorzolamide/brinzolamide/travoprost/bimatoprost/brimonidine/pilocarpine or
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brimonidine and brinzolamide). Regardless of the number of available options for topical treatment of
glaucoma, there is still a demand of using systemic drugs, and laser and surgical procedures in some
clinical cases [22,48].
Age-related macular degeneration (AMD) is a degenerative disorder affecting people over the
age of 50 years. An estimated number of people affected by AMD is approximately 30–50 million
worldwide [49]. There are two known forms of AMD. The majority of patients have so-called “dry”
AMD that is usually asymptomatic, except for gradual central visual loss of night vision. Also, it
may be accompanied by metamorphopsia and prolonged afterimages [57]. This stage is defined
by formation of drusen (amorphous deposits located between the retinal pigmented epithelium
(RPE) and the Bruch’s membrane) and abnormalities of RPE including hyperpigmentation and
atrophy. In a relatively small share of patients, this form progresses to the neovascular (“exudative”
or “wet”) AMD. This condition is characterized by the growth of new abnormal capillaries from
the choriocapillaris (choroidal neovascularization) that penetrate the Bruch’s membrane, resulting
in hemorrhages or exudation, producing scar, retina, or RPE detachment. At this stage, patients
complain of a rapid onset of visual loss, a central blind spot, or metamorphopsia. The treatment
of “dry” AMD is mostly based on changing lifestyle and using oral vitamin supplements (ascorbic
acid, vitamin E, alpha-carotene, and zinc), which are thought to delay its progression. On the other
hand, the treatment of the neovascular (“wet”) AMD should be started with intravitreal injections
of anti-vascular endothelial growth factor agents (anti-vascular endothelial growth factor (VEGF)
treatment: ranibizumab, aflibercept, pegaptanib, bevacizumab), which is an invasive procedure
posing concern and discomfort for the patient. Moreover, there are some potential vision-threatening
complications associated with intravitreal injections: infectious endophthalmitis, retinal tears, sterile
inflammation, vitreous hemorrhage, cataract, elevation of the IOP, etc. [49]. The intravitreal injection
still remains a primary delivery route of anti-VEGF agents. A serious limitation of this therapy is
a relatively short half-life of VEGF following intravitreous injections [58], which implies the need
for frequent administrations. Some approaches were recently reported to develop less invasive
methods of delivery, for example, subconjunctival administration of lyophilized matrices containing
bevacizumab [59].
The development of formulations capable of delivering anti-VEGF agents into the eye, when
administered topically, will be of great advantage and could revolutionize the therapy of this condition.
Davis et al. [60] reported the successful topical delivery of Avastin using annexin A5-associated
liposomal formulations to the posterior segment of the eye in vivo (rats and rabbits) at physiologically
significant levels. This could be considered as a major advancement that should attract further research
and perhaps some studies into the use of penetration enhancers. Some advances in the development of
topical formulations to the delivery of biopharmaceuticals to the posterior segment of the eye were
recently discussed in several reviews [61].
Photodynamic therapy (PDT) is an option if patients have any contraindications for anti-VEGF
therapy. Focal laser photocoagulation is the third solution that can be offered to a patient, which is
uncommon due to common recurrence and presence of localized scotoma after the procedure [48].
Diabetic retinopathy (DR) also belongs to one of the leading causes of vision impairment, as
prevalence of diabetes mellitus is increasing dramatically worldwide [62]. In fact, this is the most
frequent microvascular complication of diabetes. According to Duh et al. [63], almost 100 million
individuals were diagnosed with diabetic retinopathy. DR is divided into two groups: (1) the earlier
stage of non-proliferative diabetic retinopathy (NPDR), which is characterized by microaneurysms,
retinal hemorrhages, intraretinal microvascular abnormalities, and venous caliber changes; and
(2) proliferative diabetic retinopathy (PDR) with pathologic pre-retinal neovascularization. Additionally,
diabetic macular edema may occur during both NPDR and PDR, representing the most common
cause of vision loss in patients with DR. This edema arises from diabetes-induced breakdown of
the blood–retinal barrier, with consequent leakage of fluid and circulating proteins from the vessels
into the neurosensory retina [63]. As a matter of priority, assessment of patients with DR relies on
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the control of glucose concentration in the patient’s blood. The treatment of this condition involves
laser photocoagulation (panretinal, focal, and grid), intravitreal anti-VEGF agents (aflibercept and
ranibizumab), corticosteroids (dexamethasone and fluocinolone acetonide intravitreal implants), and
vitrectomy in the case of vitreous hemorrhage [48]. Some of these therapeutic approaches could
potentially benefit from the development of formulations that could deliver drugs to the eye topically.
4. Permeability of Ocular Membranes
The analysis of the physicochemical properties of various chemical compounds that cross
membranes in the eye could be key in understanding the opportunities and obstacles in ocular drug
delivery. Thus, according to Prausnitz and Noonan [64], the octanol–water partitioning coefficient
(logP), which helps characterize the drug’s hydrophilic–lipophilic properties, determines the ability of
molecules to pass through cells of the epithelial and endothelial layers of the cornea and conjunctiva.
The epithelium permeability accounts up to 90% for the lipophilic substances as a result of the high
dependence on logP, while almost totally excluding macromolecules (with radius larger than 10 Å) [64].
Hence, the epithelium is the main limitation for intracorneal drug delivery. In contrast, stromal
drug permeability is less dependent on logP but highly dependent on the radius of the molecules,
providing a great barrier for lipophilic compounds of a small size (radius < 10 Å). Interestingly, the
permeation across the endothelium layer relies on both logP and the size of the molecule (paracellular
penetration route) and is slightly more impermeable for lipophilic small molecules in comparison to
the corneal stroma. However, macromolecules cross the endothelium more easily than the stroma. The
permeability of another ocular membrane, sclera, is relatively close to that of the corneal stroma. The
data on conjunctival permeation are limited; however, according to some reports, it demonstrates a
higher permeability compared to the cornea [64].
Edwards and Prausnitz [65] reported the development of a theoretical model that can help in
predicting the permeability of the cornea for different solutes, which can be calculated using only
two parameters: radius of the molecule and logP. This could be a very useful model in ocular drug
delivery, but there are a few factors that were not taken into account by the authors: simplification of
the structure of openings between the cells, as well as tight junctions in epithelial and endothelial layers,
various permeability of cells within the epithelium layer, possible intracorneal binding of compounds,
and different shape of molecules (assuming all of them to be solid spheres).
Recently, a few in vitro and ex vivo models were used to evaluate permeability and drug absorption
by the cornea. Thus, according to Agarwal and Rupenthal [66], cell-based models are commonly used
for studies of penetration. Advantages of these models include relatively lower cost compared to the
use of laboratory animals, as well as minimizing the number of animal studies. However, this type of
model is more suitable to evaluate the cytotoxicity of the compounds rather than their permeability and
absorption by the cornea. This is because cell-based models are, in simple terms, five to six layers of
the epithelial cells of the cornea (usually, corneal culture of the rabbit) but not the entire structure of the
cornea. Additionally, these cell cultures neither have transporter molecules nor enzymes responsible
for drugs metabolism. One of the closest models to the real cornea involves reconstructed tissue
cultures which comprise different types of cells that help mimic the three-layer structure including the
epithelium, stroma, and endothelium. For example, Kaluzhny et al. [67] recently developed an in vitro
human three-dimensional corneal epithelial tissue model and demonstrated the applicability of this
membrane for studies of drug permeability using several fluorescent markers, as well as latanoprost
and bimatoprost.
Ex vivo corneas of various animals (rabbit, porcine, bovine) are also commonly used for evaluating
corneal permeability and absorption; however, this model is not ideal due to the differences in the
anatomical structure compared to the human cornea, as well as potentially different enzymes and
molecules of active transporters. Thus, rabbit eyes are commonly used as ex vivo models, but the
rabbit cornea does not have Bowman’s layer, which results in higher penetration of substances in
comparison with the human cornea. The eyeball size, thickness of the cornea, ratio of length of the
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cornea to eye-globe diameter, and histological structure (including Bowman’s membrane) in porcine
eyes are the closest to the human eye. Bovine eyes are also used in the studies of ocular tissue drug
permeability despite the fact that these are larger than human eyes and their corneal epithelium is
almost twice the thickness [66]. Loch et al. [21] conducted a comparative study of the permeation
of three different drugs (ciprofloxacin hydrochloride, lidocaine hydrochloride, and timolol maleate)
through porcine, rabbit, and bovine ocular tissues. They observed substantial differences between the
apparent permeability coefficients (Papp) for different animal species.
Papp =
Q
A×C0 , (1)
where Q is the steady-state appearance rate of the investigated substance on the acceptor side of the
tissue (mol/s), C0 is the initial concentration of the drug in the donor chamber (mol/L), and A is the
surface area of the tissue (cm2). In order to take into account the differences in the thicknesses of porcine,
rabbit, and bovine tissues, they calculated effective diffusion coefficients using the following equation:
De f f = Papp × l, (2)
where l is the tissue thickness (cm). The results of Deff determination are presented in Figure 6. These
results clearly show that the chemical nature of the drug has great influence on the tissue permeability.
The authors also hypothesized that protein binding, tissue hydration, or transporters may play some
role in the differences between different species.
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5. Penetration Enhancers
Anatomical and physiological features of the eye, ocular conditions, and permeability of ocular
membranes were discussed above, and the review now moves to consider some of the different classes
of penetration-enhancing compounds, describing their properties and modes of action.
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5.1. Cyclodextrins
Cyclodextrins (CD) are water-soluble cyclic oligosaccharides shaped like a truncated cone.
Native cyclodextrins include α-CD, β-CD, and γ-CD, which differ in the number of α-(1-4)-linked
glucopyranose subunits (six, seven, and eight, respectively, Figure 7) [68]. There were many derivatives
of CDs developed over the last decades, each bringing some improved properties such as enhanced
aqueous solubility. The most common derivatives of CDs include hydroxypropyl-β- and γ-CD,
the randomly methylated β-CD, and sulfobutylether β-CD [69]. Cyclodextrins have lipophilic
cavities and hydrophilic hydroxyl groups associated with the external surfaces of their molecule [70].
They are capable of forming guest–host inclusion complexes, whereby lipophilic drugs with poor
aqueous solubility reside within the hydrophobic cavity, where they are protected, but not covalently
bound. The drug–CD complexes usually have improved aqueous solubility due to the hydrophilic
properties of the external surface of the cyclodextrin molecule [71]. It is generally established that
only free drug molecules from topical formulations with cyclodextrins are able to penetrate ocular
membranes [72]. Since cyclodextrins are relatively large molecules, they are unable to permeate
through intact lipophilic membranes, for example, the corneal epithelium; however, they allow drugs
to interact with the epithelial surface. They have uses in pharmaceutical applications due to their drug
solubility-enhancing properties, improved bioavailability, and improved formulation stability, capable
of masking a drug’s irritation effects; they are generally regarded as safe (GRAS) [73]. Drug–CD
inclusion complex formation/dissociation is a dynamic process, where drug molecules are released
and taken up spontaneously in the aqueous environment [74,75]. Lipophilic compounds are able to
reside within the cyclodextrin molecule cavity through weak hydrophobic interactions. In the aqueous
environment of the tear film, drugs can be released from drug–CD complexes by preferential take-up
of cell-membrane lipids, such as cholesterol and phospholipids, and simultaneous ejection of the drug
guest. There remains an opportunity for the drug to enter the epithelium membrane via the temporary
disruption caused by lipid extraction during membrane–cyclodextrin interaction [68,76].
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The ability of α-CD to enhance corneal penetration for cysteamine (β-mercaptoethylamine;
medication used to treat cystinosis, which is a rare, genetic disorder with abnormal accumulation of
cystine within the corneal stroma resulting in photophobia) [78] was established by Pescina et al. [79]
in ex vivo experi ents with freshly excised pig corneas. The researchers also demonstrated lack
of irritation caused by a 5.5% α-CD solution employing the Hen’s Egg Test on the Chorioallantoic
e brane. oreover, the addition of ethylenedia ine-N,N,N’,N’-tetraacetic acid (EDTA) to α-CD
established a good stability profile of cysteamine. According to Aktas¸ et al. [80], the eye drops consisting
of pilocarpine nitrate and hydroxypropyl β-cyclodextrin (HP-β-CD) demonstrated a four-fold increase
in transcorneal penetration compared to a drug formulation without CD. The researchers used
side-by-side diffusion cells and corneas harvested from rabbits. In addition, the pupillary-response
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pattern was monitored in rabbits in vivo. The constriction of the pupil was remarkably increased
due to the addition of the HP-β-CD-containing formulation of pilocarpine nitrate. Loftsson and
Stefansson [81] designed low-viscosity eye-drop formulations with drug/γ-CD complexes which were
then tested in vivo in rabbits and clinically in patients. The first aqueous eye-drop formulation included
dorzolamide/γ-CD complexes and demonstrated high levels of the drug in the aqueous humor of
rabbit eyes more than 24 h after a single application. The IOP-lowering effect of this solution in patients
was observed after daily use compared to conventional eye drops with dorzolamide that should be
given three times a day to provide the same effect. Other eye drops consisted of dexamethasone/γ-CD
complexes and showed the ability to deliver dexamethasone to the posterior segment of the rabbit eye.
Moreover, there were significant clinical improvements in patients with diabetic macular edema (DME)
and intermediate uveitis patients with cystoid macular edema after the topical use of eye drops with
dexamethasone/γ-CD. The results for DME patients were clinically similar to those after the intravitreal
corticosteroid injection.
Morrison and co-workers [68] studied the penetration of riboflavin through freshly excised
bovine corneas using formulations containing various cyclodextrins. They established that β-CD
and HP-β-CD facilitate the permeation of riboflavin through the cornea; however, they do not affect
the lag time of approximately 90–120 min, where the first portions of the drug begin crossing the
cornea. The microscopic examination of the corneas treated with cyclodextrins indicated that these
permeability enhancers cause some disruption of the epithelial structure. Further analysis of this
disruption allowed the authors to establish the mechanism of permeability enhancement related to
the extraction of cholesterol from corneal tissue observed in the case of formulations with β-CD and
HP-β-CD. This resulted in a partial disruption of the corneal epithelia, which was evidenced from
histological examination of the bovine corneal membranes exposed to solutions of cyclodextrins for
different contact times. Figure 8 shows exemplary micrographs of corneas exposed to 30 mg·mL−1
solutions of β-CD compared to control non-exposed tissues. Samples of the cornea treated with
β-cyclodextrin showed some epithelial disruption, which became more noticeable with longer exposure
time. However, no extraction of cholesterol was observed when the corneas were exposed to water or
α-CD and γ-CD.
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5.2. Chelating Agents
The corneal epithelium offers a highly resistant barrier against alien matter due to its lipophilic
characteristics, preventing the transcellular transport of many drugs, and the existence of tight junctions,
i.e., tightly adherent regions between cells, maintaining intimate cell contact, effectively preventing
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drug transport via the paracellular route. Tight junction functionality of the superficial epithelial
cells depends on an undetermined availability of Ca2+ ions [4,82]. Calcium chelating agents are often
included in topical ocular drug formulations as stabilizers. They were shown to offer temporary and
reversible action when used for enhancement of ocular drug delivery. However, there is evidence that
ethylenediamine-N,N,N’,N’-tetraacetic acid (EDTA) in topical ocular formulations can bring side effects
due to accumulation within the iris and ciliary body, and can affect endothelial cells and capillaries
associated with the uveal tract. Caution should be exercised due to toxicity implications, especially
when medication is required in the long term [83]. Calcium chelators, a class of polyaminocarboxylic
acids, for example, EDTA, ethylene glycol-bis(beta-aminoethyl)-N,N,N’,N’-tetraacetic acid (EGTA),
1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA) [84], and ethylenediamine-N,N’
-disuccinic acid (EDDS) (Figure 9), are capable of reversibly enhancing drug penetration across
otherwise penetration-resistant barriers such as the corneal epithelium [17].
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Their ode of action is achieved via disruption of tight junctions and adherens junctions by
sequestration of interstitial a2+ ions, on hich the barrier function is dependent. esearch carried
out by orrison and hutoryanskiy [17] sho ed that lo -concentration aqueous solutions of E T ,
E T , and E S at 1 g· L−1 ere capable of extracting a2+ ions fro bovine corneas in vitro
(Figure 10). The three for ulations studied enhanced a2+ extraction and corneal penetration of
riboflavin co pared ith phosphate-buffered saline. The sa e researchers investigated per eability
enhance ent of bovine corneas in vitro using transepithelial electrical resistance analysis (TEE ),
finding that all polyaminocarboxylic acid formulations investigated lowered TEER values, correlating
with enhanced penetration of riboflavin across bovine epithelia into the corneal stroma. EGTA showed
the best performance for Ca2+ extraction and penetration enhancement from the formulations explored.
Kikuchi et al. [85] investigated a synergistic relationship for enhancing ocular drug penetration
when using a combination of EDTA and boric acid in various proportions. The researchers found that
the co-formulation brought an improvement in drug penetration across the highly resistant epithelial
membrane, but no enhancement to the already efficient permeation across de-epithelialized rabbit
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corneas. They concluded that the synergistic effects observed were due to improved transcellular
permeability when compared to formulations with either EDTA or boric acid alone [85]. Topical aqueous
ocular drug formulations incorporating polyaminocarboxylic acid penetration-enhancing agents induce
disruption to the corneal epithelium, even at concentrations as low as 1 mg·mL−1. Although this
enhances corneal permeability to drugs, it can also introduce undesirable side effects such as ocular
irritation. The use of topical ocular drug formulations incorporating mucoadhesive polymers, i.e.,
hyaluronic acid, chitosan, and alginate, together with polyaminocarboxylic acid penetration-enhancing
agents, gives the benefits from these chelating agents whilst moderating the epithelial disruptive effects,
allowing them to give moderate enhancement to ocular drug penetration without inducing irritation.
The use of mucoadhesive polymers potentially offers a means to give improved drug efficacy, low
dose, and sustained delivery with reduced issues of toxicity and minimal undesired side effects [86,87].
However, Rodriguez et al. [86] demonstrated that the combination of mucoadhesive polymers with
permeability enhancers leads to the inhibition of permeability-enhancing effects.Pharmaceutics 2019, 11, x FOR PEER REVIEW 16 of 32 
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Crown ethers were discovered accidentally by Pedersen whilst researching the development
of complexing agents for divalent cations in the 1960s. During his research, Pedersen realized that
the cyclic polyether by-products were capable of forming complexes with alkali metals [88]. Since
Pedersen’s pioneering work, many derivatives were developed [89–91], and these found uses in various
fields of science, industry, and pharmacology. Crown ethers are able to form complexes with metal ions,
as well as neutral and ionic organic molecules, and their complexes have the ability to traverse biological
membranes [92–94]. They are employed for the treatment of tumors [95,96] and drug-loaded vesicular
preparations [97,98]. Crown ethers are flexible molecules, allowing them to adapt to the environment
they are exposed to. In aqueous solutions, they interact with this medium by exposing their hydrophilic
oxygen atoms to water molecules; however, when these molecules encounter a lipophilic solvent, they
interact via their lipophilic ethylenic groups [91]. These properties, together with their ionophoric
qualities, make them ideal compounds for use in ocular drug delivery, where the formulation has to
interact with both aqueous and lipophilic phases. At the time of writing of this review, there was only
one published study investigating the use of crown ethers for enhanced ocular drug delivery [99];
Morrison et al. [100] investigated 12C4, 15C5, and 18C6 for use in ocular drug delivery, and they were
able to show enhanced aqueous solubility of riboflavin up to 46%, potentially improving bioavailability
(Table 1). Furthermore, all crown ether variants studied were capable of significantly enhancing Ca2+
extraction from bovine corneas in vitro compared with phosphate-buffered saline. In the same study
the researchers were able to show enhanced corneal delivery of riboflavin to bovine corneal stroma
in vitro with crown ether concentrations as low as 1 mg·mL−1.
Table 1. Steady-state flux and apparent permeability of riboflavin through bovine cornea in
phosphate-buffered saline (PBS) with and without crown ether. Reproduced from Reference [100] with
permission from American Chemical Society, 2017.
Solution Steady-State Flux (µmol·min−1) Papp (cm·s−1 × 10−3)
PBS 0.0478 1.945
12C4 (1 mg·mL−1) 0.1208 6.138
15C5 (1 mg·mL−1) 0.1074 5.457
18C6 (1 mg·mL−1) 0.0753 3.826
12C4 (30 mg·mL−1) 0.3410 17.326
15C5 (30 mg·mL−1) 0.1961 9.964
18C6 (30 mg·mL−1) 0.1811 9.202
Morrison et al. [100] also carried out a toxicological investigation and in vivo penetration studies
using the rat model. The toxicological investigation was able to show that crown ethers were no
more toxic to ocular tissue than benzalkonium chloride, an excipient often used at low concentrations
as a preservative in ocular drug formulations. The in vivo drug penetration study failed to show
any statistically significant permeability enhancement compared to enhancer-free formulations, the
most probable reason being due to natural clearance mechanisms that protect the eye from foreign
material. However, their in vivo study was conducted using a very limited number of animals (n = 3)
to achieve good levels of statistical significance. They concluded that further in vitro and in vivo
investigations are required to better understand crown ethers as penetration enhancers for ocular drug
formulations [100].
5.4. Surfactants
Surface active compounds (surfactants) are compounds that have lipophilic and hydrophilic
moieties. Acting on a surface, or between aqueous and non-aqueous media interfaces, surfactants
are able to reduce interfacial surface tension [101]. In pharmaceutical applications, surfactants are
commonly used as excipients to solubilize formulation components, or in the case of permeability
enhancement, they alter membrane properties by disrupting tear film and mucin, removing their
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protective properties, disrupting the integrity of the epithelia by loosening tight junctions or modifying
epithelial cell membranes. These compounds are included in formulations in a wide range of
pharmaceutical applications including oral, injectable, nasal, ocular, and transdermal, amongst others.
The polar group determines the specific properties of surfactants, and they can be classified into
four main groups: cationic, anionic, zwitterionic, and non-ionic. Cationic surfactants have a positive
charge on the polar head group, anionic surfactants have a negative charge, zwitterionic surfactants
have positive and negative charges depending on which environment they are exposed to, and
non-ionic surfactants are neutral [102]. Non-ionic surfactants are the compounds of choice for
many drug delivery scenarios including ocular drug delivery, bringing enhanced drug solubility,
formulation stability, biocompatibility, and low toxicity compared with their anionic, amphoteric, and
cationic counterparts [103,104]. Polyoxyethylene-9-lauryl ether, Tween-80 and Span-60 are non-ionic
surfactants, and their mode of action is via phospholipid acyl chain perturbation. According to Marsh
et al. [105], the 1% solutions of Tween-20 and Brij-35 showed a relatively high effectiveness in enhancing
permeability of the cornea by a five-fold increase in penetration of fluorescein through the cornea
without detected irritation of the eye. Saettone et al. [106] reported improved permeability of the
rabbit cornea for the β-blockers (atenolol, timolol, levobunolol, and betaxolol) combined with Brij-35,
-78, and -98. The increased penetration was greater for atenolol and timolol, which are hydrophilic,
than for hydrophobic β-blockers (levobunolol and betaxolol), which can be due to the hydrophilic
properties of the corneal stroma. The non-ionic surfactant d-alpha-tocopheryl poly(ethylene glycol)
1000 succinate is also a potential permeability enhancer for ocular drug delivery. Ostacolo et al. [107]
showed that this penetration enhancer effectively increased the permeation of riboflavin through
porcine corneas. Pharmasolve® (N-methyl-2-pyrrolidone) is another permeation enhancer that was
studied by Li et al. [108] for transcorneal drug delivery using rabbit eyes. Interestingly, this penetration
enhancer increased the apparent corneal permeability coefficients for ribavirin, enoxacin, puerarin,
and ibuprofen by 4.04-, 2.76-, 2.67-, and 1.47-fold, respectively. Also, no ocular irritation was observed
for formulations with less than 10% N-methyl-2-pyrrolidone. Montenegro et al. [109] demonstrated
a significant improvement in penetration of acyclovir through the rabbit corneas in the presence
of 5% N-methyl-2-pyrrolidone, positively charged phospholipid mixture, and sodium taurocholate
after 90 min since the drug was administered on the ocular surface; however, after 180 min, only the
phospholipid mixture was still effective. The taurocholate, Brij-78, and phospholipid mixture enhanced
the permeation of timolol maleate across the cornea after 90 min, but only Brij-78 showed the ability to
retain this effect after 180 min.
These are also natural surfactants produced by some plants that could be potentially useful as
penetration enhancers. Saponins are a class of amphiphilic glycosides abundantly found in different
plants that exhibit good penetration-enhancement properties. For instance, digitonin is a steroidal
saponin (Figure 12) isolated from the Digitalis purpurea plant; it is capable of solubilizing cellular
membrane lipids and cholesterol. Shih and Lee demonstrated that digitonin caused ocular epithelial
exfoliation [110–112].
Benzalkonium chloride (BAC) is a cationic surfactant that is commonly used in many formulations
for ocular drugs in low concentrations as a preservative. BAC is a known irritant even at low
concentration (<0.01%); nevertheless, it acts as a penetration enhancer, which destabilizes the tear
film and the protection offered by the mucous layer at the cornea surface. BAC also initiates changes
within phospholipid bilayers of cellular membranes [113]. Recently, Johannsdottir et al. [114] reported
an in vivo study of benzalkonium chloride’s effect on the ocular penetration of dexamethasone
in pigmented rabbits. They compared two eye-drop formulations of dexamethasone, where the
drug formed a microsuspension with γ-CD in a vehicle containing poloxamer, NaCl, and EDTA
with and without 0.02% (w/v) benzalkonium chloride. The analysis of the drug concentrations in
different ocular tissues 2 h following the eye-drop administration indicated no statistically significant
effects of benzalkonium chloride. The authors related the absence of permeability enhancement to
Pharmaceutics 2019, 11, 321 19 of 33
the quick removal of benzalkonium chloride with tear fluid and its inability to penetrate into the
cornea/conjunctiva and sclera to cause disruption of barrier function.
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Sasaki et al. [115] compared the influence of a few penetration enhancers (saponin, EDTA,
benzalkonium chloride, and paraben) on improving ocular absorption of thyrotropin-releasing
hormone and luteinizing hormone-releasing hormone using diffusion cells with rabbit conjunctiva
and cornea. The researchers showed that penetration of both hormones through the conjunctiva was
improved by 0.5% saponin, 0.05% benzalkonium chloride, and 0.01% benzalkonium chloride. The
permeability coefficient of conjunctiva was significantly improved for luteinizing hormone-releasing
hormone using EDTA and paraben. The observed effects of permeation enhancers for conjunctiva were
smaller compared to those on corneal penetration with luteinizing hormone-releasing hormone with
paraben as the exception. EDTA and saponin increased the ratios of corneal to conjunctival permeation
of both hormones. According to van der Bijl et al. [116], 0.01% benzalkonium chloride enhanced the
permeation of cyclosporin A through frozen/thawed rabbit cornea.
Transcutol® P is another solubilizer mostly used as a transdermal penetration enhancer.
Liu et al. [117] demonstrated that 0.005–0.03% Transcutol® P increased the apparent permeability
coefficient by 1.5-, 1.5-, 3.0-, and 3.3-fold for ribavirin, gatifloxacin, levofloxacin hydrochloride, and
enoxacin, respectively. Permeation for oxaprozin was inhibited with a maximum decrease by 2.8-fold
for 0.03% Transcutol® P. In addition, no irritation was observed with Transcutol® P at concentrations
of 0.005–0.03%, with the presence of slight irritation for 0.05% Transcutol® P. A non-ionic oil-in-water
surfactant, Labrasol®, is also a potential excipient as a corneal penetration enhancer. It is composed
of well-characterized polyethylene glycol (PEG) esters, a small glyceride fraction, and free PEG.
Liu et al. [118] observed no ocular surface irritation for 0.5–3.0% Labrasol® and slight irritation for
5.0% Labrasol®. The penetration of baicalin solution through the rabbit cornea was enhanced by 1.69-,
3.14-, and 2.23-fold in the presence of 1.5%, 2.0%, and 3.0% Labrasol®, respectively.
5.5. Bile Acids and Bile Salts
Bile acids are steroid acids, all forms of cholic acid, and their sodium or potassium salts, and
there are a number of derivatives that result from cholesterol metabolism in the liver which then
undergo further transformations in the intestinal tract. They are soluble in water and are involved
in the solubilization of dietary lipids within the gut. In the intestinal tract, they become conjugated
with taurine and glycine, where the sodium and potassium salts of these conjugates are termed bile
salts [119,120]. Bile acids are amphiphilic compounds naturally produced in the human digestive
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system; they are able to promote drug penetration across biological membranes. They are employed
in drug formulations for enhancement of drug penetration via many mucosal routes including
nasal, oral, buccal, ocular, pulmonary, and rectal mucosa. They are capable of forming vesicular
drug-carrying systems which are able to promote epithelial drug transport via transcellular and
paracellular routes [121]. Bile acids and bile salts have surfactant properties with an ability to form
micelles or liposomes in the aqueous environment, otherwise known as “bilosomes”; these vesicular
entities offer some interesting and novel properties in drug delivery [122]. Examples of many bile
acid/bile salt derivatives include deoxycholate, glycocholate, and taurodeoxycholate (Figure 13). They
are able to alter the rheological properties of ocular mucosal membranes [123], and the mucolytic
properties of bile salts alter the protective mucus barrier, inducing changes in membrane characteristics
allowing for enhanced drug transit into ocular tissue [4,124]. Dai et al. [125] investigated liposomes
with bile salts for the ocular delivery of tacrolimus FK506, a calcineurin inhibitor, as a model drug. The
liposomes they developed contained cholesterol (control) or bile salts (sodium taurocholate, sodium
deoxycholate, and sodium glycocholate), prepared using a thin-membrane dispersion technique,
achieving uniform particle size and drug entrapment. These liposomes exhibited controlled release of
<5% over 24 h, thus avoiding a “burst release” often seen with some ocular drug delivery systems. They
conducted ex vivo corneal permeability and in vivo corneal uptake experiments and demonstrated
that liposomes with bile salts offered enhanced transcorneal drug permeability compared to the
cholesterol-containing liposomes, enhancing the permeation of tacrolimus across the cornea up to
four-fold. Furthermore, cytotoxicity studies showed that the liposomes with sodium taurocholate
or sodium glycocholate were well tolerated, whereas those with deoxycholate showed evidence of
corneal toxicity to spontaneously derived human corneal epithelial cells and in the rabbit model. The
researchers concluded that liposomes incorporating sodium taurocholate and sodium glycocholate
offer potential as ocular drug delivery systems for drugs of low aqueous solubility such as tacrolimus,
due to their low toxicity and improved ocular permeability [125]. A cautious approach is generally
required when employing bile acids and bile salts for enhanced ocular drug delivery; however, given
the right choice of cholic acid variant or a derivative therewith, and the right choice of delivery vehicle,
bile acids and their salts offer much potential for future ocular drug delivery systems.
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Mahaling and Katti [126] recently investigated the effect of different enhancers (benzalkonium
chloride, capric acid, EDTA, sodium glycocholate, and sodium taurocholate) on the penetration of
polymeric nanoparticles in vivo in pigmented mice. It was established that sodium glycocholate and
sodium taurocholate enhanced the permeability of nanoparticles in the conjunctiva. Benzalkonium
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chloride, sodium glycocholate, and sodium taurocholate enhanced bioavailability of nanoparticles
in the iris and ciliary body. They also observed some inhibition effects; the use of EDTA decreased
the bioavailability of nanoparticles in the lens and choroid, whereas sodium glycocholate showed
a reduction in their presence in the choroid and retina. The authors concluded that a combination
of penetration enhancers with a hydrophilic mucoadhesive coating on nanoparticles is a promising
approach to enhance their bioavailability.
5.6. Cell-Penetrating Peptides
Cell-penetrating peptides (CPPs) are short chains of amino acids connected by amide bonds
(peptide bonds); they form a diverse group of compounds derived from variable combinations of
many different natural amino acid residues [127]. CPPs are capable of penetrating cellular membranes
and have the ability to transport internalized hydrophilic cargo into cells, for example, drugs [128].
Liu et al. [129] investigated a number of fluorophore-labeled cell-penetrating peptides, namely,
trans-activating transcriptional activator (TAT), penetratin, poly(arginine), low-molecular-weight
protamine, and poly(serine), for their ocular permeability using side-by-side diffusion cells, ex vivo
in a rabbit model. Protamine is a small arginine-rich protein; TAT and penetratin are complex
polypeptides consisting of specific sequences of different amino acids, whereas poly(arginine) and
poly(serine) represent homopolymers of corresponding amino acids. The structures of poly(arginine)
and poly(serine) are shown in Figure 14. They also used human conjunctival epithelial cells to
determine cytotoxicity and cellular uptake of CPPs. The researchers found penetratin to have excellent
performance in enhancing drug permeability, whilst also showing the lowest cytotoxicity. Penetratin
showed cellular uptake more than 25-fold compared with the control peptide poly(serine). This
peptide also showed an increased permeation of 87.5 times using the rabbit excised corneas. When
fluorophore-labeled penetratin was instilled into the cul-de-sac of rat eyes, it was widely distributed
in the anterior and posterior segments and could be measured in the corneal epithelium and retina
for at least 6 h. They concluded that penetratin could be a potential permeability enhancer for
ophthalmic use; this peptide can be conjugated with bioactive compounds for topical delivery into the
eye reaching as far as the retina. Further research on the design and synthesis of new cell-penetrating
peptides for topical delivery into different layers of the cornea, with potential application as absorption
enhancers for metabolic sensitive ophthalmic drugs, was recently conducted by Pescina et al. [130].
The researchers labeled the synthesized CPPs with 5-carboxyfluorescein and measured their diffusion
and distribution within the cornea using an ex vivo porcine model and confocal microscopy. The
synthesized peptides were also shown to be safe and well tolerated when tested on human conjunctival
cell line. They concluded that the tested CPPs could provide useful ocular therapies, especially
when used as transcorneal transporters for some drugs with unfavorable molecular characteristics,
examples being the aminoglycoside antibiotic, cysteamine, and antiviral agents. Interestingly, in
2017, de Cogan et al. [131] reported a promising approach for topical delivery of an anti-VEGF agent
(bevacizumab) linked to the CPP (5(6)-carboxyfluorescein–RRRRRR–COOH) to the posterior segment
of the eye. The toxicity of CPP, assessed using cell cultures, was found to be low. This complex study
was done in vivo and included optical coherence tomography (OCT) imaging of the CPP tagged with
fluorescent dye passing into the rat’s eye anterior segment, as well as assessment of topical delivery of
the complex CPP–bevacizumab into the vitreous body with subsequent fixation of the time course
of bevacizumab clearance from the vitreous body and retina. Moreover, the in vivo effectiveness of
eye drops comprising a complex formulation of CPP with anti-VEGF agent was evaluated in a mouse
model with choroidal neovascularization (CNV) which, as mentioned above, is common in patients
with neovascular AMD. Mice received different treatment, which included intravitreal injection of the
anti-VEGF agent, topical application of CPP with anti-VEGF (twice a day), or dexamethasone gavage
(every day) for 10 days. Additionally, ex vivo experiments with topical delivery of anti-VEGF agents
(ranibizumab and bevacizumab) into pig eyes were also conducted. As a result, CPP was observed
within 6 min in the anterior chamber of the eye in rats. A single application of CPP–bevacizumab
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complex on the rat’s cornea showed drug levels in the posterior segment that could be relevant to
clinical concentrations. CPP–ranibizumab and CPP–bevacizumab complex concentrations in the
posterior chamber of porcine eyes were also found to be clinically relevant. There was a significant
decrease in CNV area in all mice that received intravitreal injection, eye drops with CPP with anti-VEGF
drug, and dexamethasone gavage compared to the eyes treated with a laser only.
Pharmaceutics 2019, 11, x FOR PEER REVIEW 21 of 32 
 
and could be measured in the corneal epithelium and retina for at least 6 h. They concluded that penetratin 
could be a potential permeability enhancer for ophthalmic use; this peptide can be conjugated with 
bioactive compounds for topical delivery into the eye reaching as far as the retina. Further research on the 
design and synthesis of new cell-penetrating peptides for topical delivery into different layers of the 
cornea, with potential application as absorption enhancers for metabolic sensitive ophthalmic drugs, was 
recently conducted by Pescina et al. [130]. The researchers labeled the synthesized CPPs with 5-
carboxyfluorescein and measured their diffusion and distribution within the cornea using an ex vivo 
porcine model and confocal microscopy. The synthesized peptides were also shown to be safe and well 
tolerated when tested on human conjunctival cell line. They concluded that the tested CPPs could provide 
useful ocular therapies, especially when used as transcorneal transporters for some drugs with 
unfavorable molecular characteristics, examples being the aminoglycoside antibiotic, cysteamine, and 
antiviral agents. Interestingly, in 2017, de Cogan et al. [131] reported a promising approach for topical 
delivery of an anti-VEGF agent (bevacizumab) linked to the CPP (5(6)-carboxyfluorescein–RRRRRR–
COOH) to the posterior segment of the eye. The toxicity of CPP, assessed using cell cultures, was found 
to be low. This complex study was done in vivo and included optical coherence tomography (OCT) 
imaging of the CPP tagged with fluorescent dye passing into the rat’s eye anterior segment, as well as 
assessment of topical delivery of the complex CPP–bevacizumab into the vitreous body with subsequent 
fixation of the time course of bevacizumab clearance from the vitreous body and retina. Moreover, the in 
vivo effectiveness of eye drops comprising a complex formulation of CPP with anti-VEGF agent was 
evaluated in a mouse model with choroidal neovascularization (CNV) which, as mentioned above, is 
common in patients with neovascular AMD. Mice received different treatment, which included 
intravitreal injection of the anti-VEGF agent, topical application of CPP with anti-VEGF (twice a day), or 
dexamethasone gavage (every day) for 10 days. Additionally, ex vivo experiments with topical delivery 
of anti-VEGF agents (ranibizumab and bevacizumab) into pig eyes were also conducted. As a result, CPP 
was observed within 6 min in the anterior chamber of the eye in rats. A single application of CPP–
bevacizumab complex n the rat’s cornea showed drug levels in th  posterior segment that could be 
relevant t  clinical c centrations. CPP–rani izumab and CPP–bevacizumab complex concentrations in 
the posterior chamber of porcine yes were also found to be clinically relevant. There as a sig ifi t 
 i    i  ll i  t t i  i t it l i j ti ,   it   it  ti-  
,  exa ethasone gavage compared to the y s treated with a laser only.  
 
(a) (b) 
Figure 14. Structures of poly-L-serine (a) and poly-L-arginine hydrochloride (b). 
Nemoto et al. [132] demonstrated the permeability-enhancing features of poly-L-arginine 
hydrochloride for hydrophilic molecules (fluorescein isothiocyanate (FITC)-labeled dextran and 
pyridoxamine), across ocular membranes taken from Japanese white rabbits. The increase in Papp of 
FITC-labeled dextran in the cornea, conjunctiva, and conjunctiva/sclera composite was observed in 
the presence of poly-L-arginine (0.1 mg/mL) by 6.81-, 9.78-, and 7.91-fold, respectively. The 
permeation of pyridoxamine was also improved by adding poly-L-arginine by 7.98-, 4.67-, and 8.31-
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The authors suggested that the mechanism of this permeability enhancement lies in the ability of
poly-l-arginine to disassemble tight junction-associated proteins present in the cornea and conjunctiva.
Thus, this compound can be used as a permeability enhancer for lipophobic compounds without
producing significant damage to the epithelium.
Some progress in the application of cell-penetrating peptides in ocular drug delivery was recently
reviewed by Pescina et al. [133]. The authors highlighted this topic as an emerging area in ocular
therapeutics, which has great potential for the delivery of drugs and biopharmaceuticals both to the
anterior and posterior segments of the eye.
5.7. Other Amphiphilic Compounds
Fatty acids facilitate ocular drug permeation by altering cell-membrane properties and loosening
tight junctions. These compounds can also induce ion–pair complexation when formulated with
cationic drugs. Caprylic acid and capric acid are examples of fatty acids (Figure 15). The former
interacts with proteins, whilst the latter can affect both proteins and lipid components of cellular
membranes [111]. Capric acid was shown to enhance ocular penetration of β-blockers, bringing
moderate enhancement to the penetration of hydrophilic β-blockers, whilst only offering slight
enhancement for lipophilic β-blockers [123]. Kato and Iwata attributed the penetration-enhancing
effects of fatty acids for bunazosin to ion–pair interactions [134,135].
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Gelucires are glyceride-based compounds with amphiphilic surfactant properties. Gelucires 
comprise mono-, di-, and triglycerides with mono- and diesters of polyethylene glycol [136]. The 
numbers 44 and 14 in the name of Gelucire 44/14 indicate the melting temperature of 44 °C and a 
hydrophilic–lipophilic balance of 14. Known for their drug absorption-enhancing performance, 
Gelucires have a good safety profile for pharmaceutical formulations and are “generally regarded as 
safe” (GRAS). Gelucire 44/14 was evaluated as a potential permeability enhancer in vitro and in vivo 
using different ophthalmic drugs and was shown to enhance transcorneal permeability of drugs with 
a range of hydrophilicity/lipophilicity whilst remaining safe to use and non-irritating [5,20]. Another 
potential corneal permeability enhancer is Azone™ (1-dodecylazacycloheptan-2-one), which is 
currently used mostly for transdermal drug delivery. This formulation is thought to act by 
partitioning into lipid bilayers of the bio-membrane and, as a result, disrupting its structure. Tang-
Liu et al. [137] compared effects of four permeation enhancers (Azone™, hexamethylenelauramide, 
hexamethyleneoctanamide, and decylmethylsulfoxide (Figure 16)) with lipophobic (acetazolamide, 
cimetidine, guanethidine, and sulfacetamide), moderately hydrophobic (bunolol and prednisolone), 
and hydrophobic (flurbiprofen and its amide analogue) drugs through the rabbit cornea.  
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Figure 16. Structures of Azone™ (a), hexamethylenelauramide (b), hexamethyleneoctanamide (c), 
and decylmethylsulfoxide (d). 
Gelucires are glyceride-based co pounds ith a phiphilic surfactant properties. Gelucires
co prise ono-, di-, and triglycerides ith ono- and diesters of polyethylene glycol [136]. The
nu bers 44 and 14 in the na e of Gelucire 44/14 indicate the melting temperature of 44 ◦C and
a hydrophilic–lipophilic balance of 14. Known for their drug absorption-enhancing perfor ance,
elucires have a good safety profile for phar aceutical for ulations and are “generally regarded as
safe” ( R S). elucire 44/14 as evaluated as a potential per eability enhancer in vitro and in vivo
using different ophthal ic drugs and was shown to enhance transcorneal permeability of drugs with a
range of hydrophilicity/lipophilicity whilst remaining safe to use and non-irritating [5,20]. nother
potential corneal permeability enhancer is Azone™ (1-dodecylazacycloheptan-2-one), which is currently
used mostly for transdermal drug delivery. This formulation is thought to act by partitioning into lipid
bilayers of the bio-membrane and, as a result, disrupting its structure. Tang-Liu et al. [137] compared
effects of four per eation enhancers (Azone™, hexamethylenelauramide, hexamethyleneoctana ide,
and decylmethylsulfoxide (Figure 16)) with lipophobic (acetazolamide, cimetidine, guanethidine, and
sulfacetamide), moderately hydrophobic (bunolol and prednisolone), and hydrophobic (flurbiprofen
and its amide analogue) drugs through the rabbit cornea.
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The researchers demonstrated that 0.1% Azone™ enhanced the permeability of lipophobic
formulations 20-fold, while permeation of moderately hydrophobic compounds was enhanced at
0.025–0.1% Azone™ by two- to five-fold. Interestingly, there was inhibition instead of promotion of
corneal permeability for flurbiprofen and its amide analogue in the presence of Azone™. Also, all four
penetration enhancers used in this study showed similar ability to promote penetration through the
cornea for cimetidine. Additionally, the researchers noticed a parabolic relationship between the rate of
drug penetration and the lipophilicity of this compound. Afouna et al. [138] also tested gel formulations
with Azone™ as a permeability enhancer, Carbopol-974® as a mucoadhesive, and s-timolol maleate
as a model drug using rabbits. It was demonstrated that in vivo reduction of intraocular pressure
for these formulations lasted roughly 3–4 times longer in comparison with the conventional timolol
maleate eye drops. In 2016, Afouna et al. [139] reported the extension of in vitro parameters including
release, onset, magnitude, and action duration up to two days for the gel formulations containing
Azone™, Carbopol-974®, and latanoprost acid.
Borneol is a terpene derivative that can also be used as ocular penetration enhancer (Figure 17).
According to Yang et al. [140], 0.1% synthetic borneol improved the permeability of two hydrophobic
compounds (indomethacin and dexamethasone) through rabbit corneas by 1.23-and 2.40-fold,
respectively, while the permeation of more hydrophilic drugs (ofloxacin, ribavirin, and tobramycin) was
Pharmaceutics 2019, 11, 321 24 of 33
increased by 1.87-, 2.80-, and 3.89-fold, respectively. Natural borneol also enhanced the permeability
with the following levels: 1.67, 2.00, 2.15, 2.18, and 3.39, respectively. It was also established that 0.1%
borneol did not produce any damage to the cornea. The authors suggested that borneol’s ability of
promoting corneal permeability might be due to the changes in the arrangement of lipid molecules
in the cell membrane of corneal epitheliocytes, increasing the orderliness of the molecular chains
of lecithin.
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Semifluorinated alkanes (SFAs) belong to the group of amphiphilic liquids that can dissolve
lipophilic compounds forming clear solutions. Agarwal et al. [142] assessed the potential of two different
SFAs for topical ocular drug delivery. Cyclosporin A (CsA) was dissolved in perfluorobutylpentane
(F4H5) or perfluorohexyloctane (F6H8) and was compared with commercially available CsA ophthalmic
emulsions, Restasis® and Ikervis®, in terms of corneal availability. The penetration of CsA through the
cornea was evaluated by plotting the concentration of the corneal CsA per g of cornea (ng/g) against
time and determining the mean area under curve of each formulation tested over 4 h (AUC (0–4 h))
(Figure 19). The permeability of the cornea was significantly enhanced for CsA after a single dose of
0.05% CsA in F4H5 and F6H8 was applied when compared to Restasis with the area under the curve
over 4 h (AUC (0–4 h)) being at least eight-fold higher for both SFAs. Interestingly, the AUC (0–4 h) of
0.1% CsA in F4H5 was almost five-fold higher than with Ikervis. Thus, semifluorinated alkane-based
CsA formulations may improve the therapeutic efficacy.
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6. Comparison of Different Penetration Enhancers
Different classes of penetration enhancers considered in this review are summarized in Table 2.
Some of these comp unds, such as EDTA and be zalkonium c loride, are already commonly used in
ophthalmic for ulations with different roles, e.g., as a buffering agent and antimicrobial preservative,
respect vely. However, these compounds may provide some permeability enhan ement as an extra
b nefit. Cyclod xtrins are used in some pharmaceutical formulations to facilitate the solubility of
poorly soluble drugs; additionally, they could provide permeability-enhancing propert es. Othe
amphiphilic molecules such as bile acids and AzoneTM have established safety profiles but are not yet
used in commercial ocular formulations. Crown ethers represent a relatively new class of permeability
enhancers that will require more research into their efficiency and toxicological profile. Cell-penetrating
peptides are highly promising permeability enhancers that received a lot of interest in the recent decade;
more research is expected with these materials as they could potentially provide opportunities for
formulating topical products for the delivery of biologicals.
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Table 2. Different classes of penetration enhancers, their commercial applications, and possible mechanisms of action. EDTA—ethylenediamine-N,N,N’,N’-tetraacetic
acid; TAT—trans-activating transcriptional activator; FDA—Food and Drug Administration.
Class of Enhancers Examples of Compounds Commercial Applications in Drug Delivery Possible Mechanism ofPenetration Enhancement
Cyclodextrins α-, β-, γ-cyclodextrins
Some cyclodextrins are already used in commercial
ocular formulations, e.g., Vitaseptol eye drops
(Novartis). They are often used as enhancers of
drug solubility.
Extraction of cholesterol and lipids
from ocular membranes [68].
Chelating agents EDTA Disodium-EDTA is commonly used in ocularformulations as a buffering agent [143].
Extraction of Ca2+ from tight
junctions [17].
Crown ethers
12-crown-4,
15-crown-5,
18-crown-6
None of these are currently used in commercial
formulations for drug delivery.
Extraction of Ca2+ from tight
junctions [100].
Surfactants Benzalkonium chloride Around 74% of ophthalmic preparations havebenzalkonium chloride as a preservative [144].
Morphological changes in the
epithelium [145].
Bile acids and salts Deoxycholate, glycocholate,taurodeoxycholate
None of these are currently used in commercial
formulations for drug delivery.
Different mechanisms leading to
modification of the integrity of the
corneal epithelium [121].
Cell-penetrating peptides TAT, penetratin, poly(arginine),and poly(serine)
None of these are currently used in commercial
formulations for drug delivery.
Direct translocation and
endocytosis [133].
Other amphiphilic compounds Azone™
Designed and widely researched mostly as a skin
penetration enhancer. No FDA-approved products
containing AzoneTM on the market yet. It is
recorded in Chinese Pharmacopoeia and widely
used in China [146,147].
Changes in the structure and fluidity
of biological membranes; facilitation
of water influx leading to a more
hydrated barrier [137].
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7. Conclusions
Topical drug application is the most widely used treatment in ophthalmology due to its simplicity.
However, some obstacles including low permeability of the cornea, tear reflex, blinking, and
nasolacrimal drainage hamper drug delivery in this way. The analysis of physicochemical properties
of various chemical compounds that cross ocular membranes, coupled with the histological structure
of cornea, sclera, and conjunctiva, could be key in understanding the opportunities and obstacles in the
ocular drug delivery. Penetration enhancers facilitate delivery of active pharmaceutical compounds
through three main mechanisms or their combination: altering tear film stability and the mucous layer
at the ocular surface, modifying membrane components such as lipid bilayers of associated epithelial
cells, and loosening epithelial tight junctions. The variety of penetration enhancers (cyclodextrins,
chelating agents, crown ethers, bile acids and bile salts, cell-penetrating peptides, and other amphiphilic
compounds) enables an increase in the permeability of ocular membranes. However, ocular drug
delivery remains one of the toughest problems in ophthalmology, and new formulations still need to be
developed to allow better control of drug delivery and improved performance, whilst also minimizing
undesired side effects.
Different penetration enhancers were identified and mechanisms of their action were researched
in the past several decades. Many of these enhancers were also evaluated for their potential harmful
effects on the eye. However, these toxicological studies were often done to evaluate short-term exposure
of the ocular tissues to enhancers. Very little is known on the longer-term exposure and potential
chronic applications.
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